A Phase 2, Single Arm Study of Luspatercept for the Treatment of Anemia in Lower Risk Myelodysplastic Syndromes (MDS) or Non-Proliferative Myelodysplastic Syndromes/ Myeloproliferative Neoplasms (MDS/MPN)
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 70 patients (estimated)
- Sponsors
- Moffitt Cancer Center
- Collaborators
- Bristol Myers Squibb
- Tags
- Erythroid Maturation Agent (EMA), Red Blood Cell Stimulant
- Trial Type
- Supportive
- Last Update
- 4 weeks ago
- SparkCures ID
- 1539
- NCT Identifier
- NCT05732961
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.